Pacira BioSciences' Non-Current Debt rose 25199.67% to $376.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.7 million, marking a year-over-year increase of 25199.67%. This contributed to the annual value of $383.5 million for FY2024, which is 23293.26% up from last year.
As of Q3 2025, Pacira BioSciences' Non-Current Debt stood at $376.7 million, which was up 25199.67% from $97.8 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Non-Current Debt registered a high of $383.5 million during Q4 2024, and its lowest value of $97.8 million during Q2 2025.
Moreover, its 5-year median value for Non-Current Debt was $136.2 million (2023), whereas its average is $208.5 million.
As far as peak fluctuations go, Pacira BioSciences' Non-Current Debt crashed by 6192.81% in 2023, and later surged by 25199.67% in 2025.
Pacira BioSciences' Non-Current Debt (Quarter) stood at $335.3 million in 2021, then decreased by 25.12% to $251.1 million in 2022, then plummeted by 54.11% to $115.2 million in 2023, then skyrocketed by 232.93% to $383.5 million in 2024, then fell by 1.78% to $376.7 million in 2025.
Its last three reported values are $376.7 million in Q3 2025, $97.8 million for Q2 2025, and $101.5 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value